BiotechTube

milatuzumab

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

GVHD (Acute or Chronic)

Conditions

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)

Trial Timeline

Dec 1, 2013 → Mar 1, 2015

NCT ID
NCT01663766

About milatuzumab

milatuzumab is a phase 1 stage product being developed by Gilead Sciences for GVHD (Acute or Chronic). The current trial status is terminated. This product is registered under clinical trial identifier NCT01663766. Target conditions include GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome.

What happened to similar drugs?

0 of 5 similar drugs in GVHD (Acute or Chronic) were approved

Approved (0) Terminated (0) Active (5)
🔄Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
🔄remestemcel-LMesoblastPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01663766Phase 1Terminated
NCT00868478Phase 1/2UNKNOWN
NCT00603668Phase 1/2Completed
NCT00421525Phase 1/2Completed

Competing Products

19 competing products in GVHD (Acute or Chronic)

See all competitors
ProductCompanyStageHype Score
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
RituximabRochePhase 2
31
Efavaleukin AlfaAmgenPhase 1/2
24
AMG 592AmgenPhase 1
29
AMG 592AmgenPhase 1
29
Itacitinib + Prednisone + MethylprednisoloneInnovent BiologicsPhase 1/2
24
Cyclophosphamide + abatacept + Methotrexate + TacrolimusBristol Myers SquibbPhase 2
35
ALD518 + ALD518 + ALD518CSLPhase 1/2
24
Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
40
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
44
RuxolitinibIncytePre-clinical
23
Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
37
Ruxolitinib + PrednisoneIncytePhase 2
39
Itacitinib (200 mg) + Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)IncytePhase 1
26
Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
37
Ruxolitinib + Prednisone or methylprednisoloneIncytePhase 2
32
RuxolitinibIncytePre-clinical
23
Itacitinib + TocilizumabIncytePhase 1
18
remestemcel-LMesoblastPhase 3
34